These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18397298)

  • 1. Prolonged neurophysiologic effects of levetiracetam after oral administration in humans.
    Epstein CM; Girard-Siqueira L; Ehrenberg JA
    Epilepsia; 2008 Jul; 49(7):1169-73. PubMed ID: 18397298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function--a TMS study.
    Reis J; Wentrup A; Hamer HM; Mueller HH; Knake S; Tergau F; Oertel WH; Rosenow F
    Epilepsy Res; 2004 Nov; 62(1):41-51. PubMed ID: 15519131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.
    Patterson EE; Goel V; Cloyd JC; O'Brien TD; Fisher JE; Dunn AW; Leppik IE
    J Vet Pharmacol Ther; 2008 Jun; 31(3):253-8. PubMed ID: 18471147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam.
    Meador KJ; Gevins A; Loring DW; McEvoy LK; Ray PG; Smith ME; Motamedi GK; Evans BM; Baum C
    Neurology; 2007 Nov; 69(22):2076-84. PubMed ID: 18040014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and efficacy of oral loading of levetiracetam.
    Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
    Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission.
    Yang XF; Weisenfeld A; Rothman SM
    Epilepsia; 2007 Oct; 48(10):1861-9. PubMed ID: 17521346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of levetiracetam on absence seizures in a novel absence-like epilepsy animal model, Groggy rat.
    Tokuda S; Sofue N; Ohno Y; Sasa M; Serikawa T
    Brain Res; 2010 Nov; 1359():298-303. PubMed ID: 20816676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers.
    Mecarelli O; Vicenzini E; Pulitano P; Vanacore N; Romolo FS; Di Piero V; Lenzi GL; Accornero N
    Ann Pharmacother; 2004 Nov; 38(11):1816-22. PubMed ID: 15367726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of levetiracetam on sleep in normal volunteers.
    Bazil CW; Battista J; Basner RC
    Epilepsy Behav; 2005 Nov; 7(3):539-42. PubMed ID: 16165400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive and negative psychotropic effects of levetiracetam.
    Helmstaedter C; Fritz NE; Kockelmann E; Kosanetzky N; Elger CE
    Epilepsy Behav; 2008 Oct; 13(3):535-41. PubMed ID: 18583196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam.
    Novy J; Hubschmid M; Michel P; Rossetti AO
    Epilepsy Behav; 2008 Oct; 13(3):564-6. PubMed ID: 18589001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W; Shaw J; Bloom M; Gebeline-Myers C
    Headache; 2008; 48(10):1490-8. PubMed ID: 19076647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model.
    Vinogradova LV; van Rijn CM
    Epilepsia; 2008 Jul; 49(7):1160-8. PubMed ID: 18397292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
    Richy FF; Banerjee S; Brabant Y; Helmers S
    Epilepsy Behav; 2009 Oct; 16(2):240-5. PubMed ID: 19699156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saliva and serum levetiracetam concentrations in patients with epilepsy.
    Mecarelli O; Li Voti P; Pro S; Romolo FS; Rotolo M; Pulitano P; Accornero N; Vanacore N
    Ther Drug Monit; 2007 Jun; 29(3):313-8. PubMed ID: 17529888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study.
    López-Góngora M; Martínez-Domeño A; García C; Escartín A
    Epileptic Disord; 2008 Dec; 10(4):297-305. PubMed ID: 19017572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam pharmacokinetics in neonates at birth.
    Allegaert K; Lewi L; Naulaers G; Lagae L
    Epilepsia; 2006 Jun; 47(6):1068-9. PubMed ID: 16822254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
    Uges JW; van Huizen MD; Engelsman J; Wilms EB; Touw DJ; Peeters E; Vecht CJ
    Epilepsia; 2009 Mar; 50(3):415-21. PubMed ID: 19054418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of levetiracetam on cognition: a non-interventional surveillance study.
    Helmstaedter C; Witt JA
    Epilepsy Behav; 2008 Nov; 13(4):642-9. PubMed ID: 18707022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.